Quick Answer
Mirum Pharmaceuticals, Inc. reported Total Revenue of $521.31 million for fiscal year 2025.
Mirum Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $521.31M +54.7% |
$336.89M +80.8% |
$186.37M +141.8% |
$77.06M +302.7% |
$19.14M | $0.00 |
| Revenue (ASC 606) | $521.31M +54.7% |
$336.89M +80.8% |
$186.37M +141.8% |
$77.06M +302.7% |
$19.14M | — |
| Net Income | -$23.36M +73.4% |
-$87.94M +46.2% |
-$163.41M -20.5% |
-$135.66M -61.5% |
-$83.99M +18.7% |
-$103.27M -96.5% |
| Diluted EPS | -$0.47 +74.6% |
-$1.85 +53.8% |
-$4.00 +0.5% |
-$4.02 -45.1% |
-$2.77 | — |
| Total Assets | $842.81M +25.7% |
$670.75M +3.7% |
$646.62M +83.2% |
$352.91M +19.8% |
$294.65M +22.3% |
$240.86M +64.2% |
| Cash and Equivalents | $296.68M +33.3% |
$222.50M -22.3% |
$286.33M +922.5% |
$28.00M -10.6% |
$31.34M -77.9% |
$142.09M +1087.0% |
| Stockholders Equity | $314.69M +39.5% |
$225.64M -9.3% |
$248.67M +75.1% |
$142.04M +18.2% |
$120.21M -30.1% |
$172.09M +32.0% |
| Operating Income | -$22.14M +74.7% |
-$87.61M +19.7% |
-$109.15M +16.8% |
-$131.22M +24.3% |
-$173.41M -66.3% |
-$104.30M -90.5% |
| Shares Outstanding | 51.90M +7.4% |
48.34M +3.5% |
46.72M +26.4% |
36.96M +20.8% |
30.58M +2.7% |
29.78M +31.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $133.01M | +47.2% | +4.1% |
| Revenue (ASC 606) | September 30, 2025 | $133.01M | +47.2% | +4.1% |
| Net Income | September 30, 2025 | $2.90M | +120.4% | +149.6% |
| Diluted EPS | September 30, 2025 | $0.05 | +116.7% | +141.7% |
| Total Assets | September 30, 2025 | $785.12M | +17.6% | +8.2% |
| Cash and Equivalents | September 30, 2025 | $282.02M | +26.5% | +23.6% |
| Stockholders Equity | September 30, 2025 | $292.05M | +25.9% | +14.5% |
| R&D Expense | September 30, 2019 | $12.16M | +405200.0% | +4.9% |
| Operating Income | September 30, 2025 | $2.60M | +120.5% | +152.2% |
| Shares Outstanding | September 30, 2025 | 51.31M | +7.0% | +2.5% |
- Mirum Pharmaceuticals, Inc. reported Total Revenue of $521.31 million for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +54.7% in Total Revenue compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Revenue (ASC 606) of $521.31 million for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +54.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Net Income of -$23.36 million for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +73.4% in Net Income compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +74.6% in Diluted EPS compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Total Assets of $842.81 million for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +25.7% in Total Assets compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Cash and Equivalents of $296.68 million for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +33.3% in Cash and Equivalents compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Stockholders Equity of $314.69 million for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +39.5% in Stockholders Equity compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Operating Income of -$22.14 million for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +74.7% in Operating Income compared to the prior fiscal year.
- Mirum Pharmaceuticals, Inc. reported Shares Outstanding of 51.90 million shares for fiscal year 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +7.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: